Coastlands Capital Partners discloses 9.98% passive stake in Adial Pharmaceuticals

scanx
Reviewed by
Naman SScanX News Team
Key Highlights

Coastlands Capital Partners disclosed a 9.98% passive stake in Adial Pharmaceuticals as of June 17 via an SEC Form 13G filing.

powered bylight_fuzz_icon
43861517

*this image is generated using AI for illustrative purposes only.

Coastlands Capital Partners disclosed a 9.98% passive stake in Adial Pharmaceuticals as of June 17. The investment was detailed in a Schedule 13G filing submitted to the U.S. Securities and Exchange Commission (SEC).

Filing Details

The filing indicates that Coastlands Capital Partners holds the stake in a passive capacity. The SEC Form 13G is used by institutional investors to report their ownership of shares exceeding 5% when they do not intend to exert control over the issuer.

Stakeholder Information

Entity Stake Percentage Date
Coastlands Capital Partners 9.98% June 17

The disclosure provides transparency regarding significant ownership positions in Adial Pharmaceuticals.

What are Coastlands Capital Partners' strategic intentions with their near-10% stake in Adial Pharmaceuticals?

How might this significant ownership influence Adial Pharmaceuticals' future business decisions or strategic direction?

Could this stake signal potential upcoming collaborations or partnerships for Adial Pharmaceuticals?

like18
dislike

Lucid Capital initiates coverage on Adial with Buy rating

scanx
Reviewed by
Radhika SScanX News Team
Key Highlights

Lucid Capital Markets analyst Elemer Piros has initiated coverage on Adial Pharmaceuticals with a Buy rating and a price target of $6. This move provides a new valuation benchmark for investors.

powered bylight_fuzz_icon
43091622

*this image is generated using AI for illustrative purposes only.

Lucid Capital Markets analyst Elemer Piros has initiated coverage on Adial Pharmaceuticals with a Buy rating and a price target of $6. This rating indicates a positive outlook for the company's stock performance.

The coverage initiation provides a new valuation benchmark for investors following the pharmaceutical company. The price target of $6 suggests potential upside from current trading levels.

Adial Pharmaceuticals is listed on NASDAQ under the ticker symbol ADIL.

What specific factors or milestones does Lucid Capital Markets expect Adial Pharmaceuticals to achieve to reach the $6 price target?

How might this new coverage and Buy rating influence institutional investor interest in Adial Pharmaceuticals?

What are the potential risks or challenges that could prevent Adial Pharmaceuticals from realizing the projected upside?

like17
dislike

More News on Adial Pharmaceuticals Inc